AMES, Iowa-based vaccine producer Harrisvaccines announced Jan. 30 that it has been granted U.S. Department of Agriculture autogenous licensure of the company's rotavirus C vaccine utilizing its SirraVax RNA Particle Technology, which was approved by USDA's Center for Veterinary Biologics for disease caused by rotavirus subtype C.
Rotavirus C is a cause of diarrhea and mortality in young piglets. Preparing effective vaccines using traditional methods is difficult due to the poor growth characteristics of rotavirus C in laboratory cell culture.
"Our technology does not require the growth of live virus for production; only a gene sequence is needed, which allows us to hurdle many of the issues traditional vaccine production faces with rotavirus C," Jodi French, head of regulatory affairs and quality assurance for Harrisvaccines, said.
This is the first time the company's SirraVaxtechnology has been granted an autogenous license. Harrisvaccines received a USDA license using SirraVax technology for swine influenza vaccine RNA in September 2012, which is licensed as an aid in the prevention of disease caused by H3N2 swine influenza.
Harrisvaccines has also submitted a conditional license application for porcine epidemic diarrhea virus, which the company said is anticipated to gain approval this year.